Athira Pharma Q1 net loss $27.8M; focuses Alzheimer's trial on 40 mg dose

LeonaBio, Inc.

2023-Q1 EPS reported -$0.73

Net loss $27.8M ($0.73/share) vs $21.0M ($0.56) in Q1 2022; cash $219.9M.
Phase 2/3 LIFT-AD trial to focus on 40 mg fosgonimeton; 70 mg arm discontinued.
Open-label extension extended to up to 30 months; >85% enrollment from prior trials.
ATH-1105 preclinical data in ALS shows prolonged survival and improved motor function; IND-enabling work for 2024 first-in-human.
End of Phase 2 meeting with FDA scheduled for summer 2023; timeline update expected.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LeonaBio, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.